News ArticleConcord Biotech Announces Q2 and Half Year Unaudited Results for 2026 and Sets Bonus Share Record Date
Board approves standalone and consolidated results for period ending September 30, 2026; record date for bonus shares fixed on November 4, 2026
Concord Biotech Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company also fixed November 4, 2026, as the record date for issuance of bonus equity shares and reconstituted key board committees.
Concord Biotech Limited
Financial Results
Concord Biotech Limited disclosed its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, alongside fixing November 4, 2026, as the record date for bonus equity share issuance.
The Board of Directors approved the unaudited financial results following a review by the Audit Committee. These results cover both standalone and consolidated financial statements for the second quarter and half year ending September 30, 2026.
The company set Wednesday, November 4, 2026, as the record date to identify shareholders eligible to receive bonus equity shares. Further disclosures on this allotment will be provided to the stock exchanges.
In addition to financial approvals, Concord Biotech reconstituted its Audit Committee, Nomination and Remuneration Committee, Risk Management Committee, and Corporate Social Responsibility Committee to comply with SEBI regulations.
Limited review reports for the financial results were issued by the statutory auditors BSR & Co. LLP, confirming no material misstatements, although some subsidiaries’ interim financials were reviewed by other auditors or remained unaudited as disclosed.
The Board meeting convened at 3:30 PM and concluded at 4:45 PM on October 27, 2026.
Highlights
- Unaudited standalone and consolidated Q2 and H1 results approved for September 30, 2026 period.
- Record date for bonus shares fixed as November 4, 2026.
- Key board committees restructured as per SEBI Listing Regulations.
- Limited review completed by BSR & Co. LLP with no qualifications.
- Board meeting held on October 27, 2026, from 3:30 PM to 4:45 PM.
Key Data Snapshot
What happened
- Board approved unaudited standalone and consolidated financial results for Q2 and H1 ending September 30, 2026.
- Record date for allotting bonus equity shares fixed on November 4, 2026.
- Board reconstituted Audit Committee, Nomination and Remuneration Committee, Risk Management Committee, and Corporate Social Responsibility Committee.
- Limited review reports issued by statutory auditors BSR & Co. LLP with no material concerns noted.
- Subsidiary financials either reviewed by other auditors or unaudited as disclosed in filing.
Regulatory and governance context
- Financial results comply with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Reconstitution of board committees adheres to SEBI regulations concerning committee composition and governance.
- Limited review engagement conducted as per Indian Accounting Standard 34 and auditing standards.
- Disclosure submitted to both National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
Highlights
- Unaudited standalone and consolidated Q2 and H1 results approved for September 30, 2026 period.
- Record date for bonus shares fixed as November 4, 2026.
- Key board committees restructured as per SEBI Listing Regulations.
- Limited review completed by BSR & Co. LLP with no qualifications.
- Board meeting held on October 27, 2026, from 3:30 PM to 4:45 PM.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Indian Accounting Standard 34 “Interim Financial Reporting”
- Standard on Review Engagements (SRE) 2410
Source Information
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Welspun Corp Reports Q2 FY2027 Financials and Approves $115M US Capacity Expansion and $125M Jordan JV
Welspun Corp Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026, approved a $115 million capital expenditure to expand its US HSAW spiral pipe facility by 225 KMTPA, and sanctioned a $125 million joint venture with Perma-Pipe to establish spiral pipe manufacturing and coating facilities in Jordan.
Read Full Story
Ambuja Cements Acquires 26% Equity Stake in SWE Renewables and Reports Q2 FY2027 Financials
Ambuja Cements Limited has acquired a 26% stake in renewable energy firm SWE Renewables Limited and announced its unaudited financial results for the quarter and half year ended September 30, 2026, showing a profit after tax of ₹618 crore for the half year.
Read Full Story
Asian Paints Declares Rs. 5.75 Interim Dividend Alongside Q2 and H1 FY 2027 Financial Results
Asian Paints Limited announced its audited standalone and unaudited consolidated financial results for the quarter and half year ended 30th September 2026. The company also declared an interim dividend of Rs. 5.75 per equity share for the financial year ending 31st March 2027.
Read Full Story
